Deinove (XPAR:ALDEI) Current Accrued Expense : €0.00 Mil (As of Jun. 2022)

View and export this data going back to 2010. Start your Free Trial

What is Deinove Current Accrued Expense?

Deinove's Current Accrued Expense for the quarter that ended in Jun. 2022 was €0.00 Mil.

Deinove Current Accrued Expense Historical Data

The historical data trend for Deinove's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deinove Current Accrued Expense Chart

Deinove Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Current Accrued Expense

Get a 7-Day Free Trial

Deinove Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Deinove Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Deinove Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Deinove's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Deinove (XPAR:ALDEI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Deinove SA (XPAR:ALDEI) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1682 rue de la Valsiere, Cap Sigma, ZAC Euromedecine II, Grabels, FRA, 34790

Website

http://www.deinove.com

Deinove SA is a biotechnology company engaged in the development of technologies and molecules for the health, nutrition and cosmetics industries. It is developing in two areas of activity, New-generation anti-infective ANTIBIOTICS which involves the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the challenges of antibiotic resistance; and BIOACTIVES, natural active ingredients discovers, develops and produces bioactives, active ingredients of natural origin from its bacterial biodiversity bank, to invent the new generation of sustainable cosmetics and intends to quickly bring its know-how and its products to other fields, such as nutrition and health.

Deinove (XPAR:ALDEI) Headlines

No Headlines